Avid Bioservices

Overview

Avid Bioservices is a dedicated biologics contract development and manufacturing organization (CDMO) focused entirely on helping biotech and pharmaceutical companies bring innovative therapies to market. Operating from two campuses in Orange County, California, with more than 213,000 square feet of development and manufacturing space, Avid combines scientific expertise, integrated capabilities, and a partnership-driven approach.

Core Capabilities

Mammalian Cell Culture Platform

• Cell line development: creation of stable, high-producing cell lines
• Process development: scalable upstream and downstream processes
• Analytical development: data supporting quality and regulatory submissions
• Formulation development: stability and shelf-life optimization

Manufacturing Services

• CGMP clinical manufacturing for trials
• CGMP commercial manufacturing with validated processes
• Tech transfer from development to manufacturing
• Fed-batch, perfusion, and continuous processing strategies

Molecule Expertise

• Monoclonal antibodies
• Antibody-drug conjugates (ADCs)
• Bispecific and multispecific antibodies
• Fc fusion proteins
• Complex recombinant proteins
• IgGs and biosimilars
• Enzymes, cytokines, and protein-based vaccines

Program Pathways

• DNA to IND: Build scalable foundation with cell line, process, analytical, and formulation development
• IND to BLA: Advance with control through process characterization, tech transfer, and quality clinical manufacturing
• BLA to Commercial: Deliver commercial supply through validated CGMP manufacturing

Regulatory Track Record

• More than 650 total batches produced
• Decades of biologics manufacturing experience
• Successful pre-approval and pre-license inspections
• Multiple commercial products approved and marketed globally
• FDA-inspected facilities in California

Differentiation

• End-to-end integration: Development and manufacturing within one system under unified quality standards
• U.S.-based operations: All development and manufacturing conducted in California, aligned with regulatory and supply chain expectations
• Dedicated focus: Biologics development and manufacturing is the sole business focus
• Partnership approach: Direct collaboration with scientific and leadership teams; dedicated cross-functional teams provide direct access to expertise
• Scalable infrastructure: Designed to support programs at every stage from benchtop through commercial manufacturing
• Continuity of execution: One team supporting programs from start to finish